The new anti-cancer therapy is being brought to patients with the help of the Children’s Oncology Drug Alliance (CODA) which brings together UNSW researchers, childhood cancer charity The Kids’ Cancer Project, Australian biotech company Novogen and the Nationwide Children’s Hospital in Columbus, Ohio.
Neuroblastoma, the type of cancer the therapy has been developed to fight, affects up to 100 children a year in Australia, and 650 in the U.S. Previously, chemotherapy was the recommended course of action against the disease, but such a treatment can be difficult on children.
The therapy itself uses a drug class called anti-tropomyosins, which can be tailored to attack the structure of the cancer cell without affecting nearby healthy cells.
Dean of UNSW Medicine, Professor Peter Smith, said that the new anti-cancer therapy developed by CODA had “…the potential to be the most significant development in the treatment of childhood cancer in more than 20 years.”
Novogen, since acquiring the anti-tropomyosin technology in 2013, has only increased the “potency, selectivity and safety profile” of the new drugs, said Novogen CEO Dr Graham Kelly.
The Kids’ Cancer Project, which has supported the program since research at UNSW began in 1998, has provided over $9 million in funding to date, and needs more funding to ensure that the next research phase is not delayed.
To find out more visit: http://newsroom.unsw.edu.au/news/health/fast-tracking-new-treatment-childhood-cancer
To donate visit: https://www.thekidscancerproject.org.au/get-involved/Donate.aspx
[img source] db Photography – D. Brooke (CCA2.0) bit.ly/1odOrki